Skip to main content
. 2021 Nov 24;57(12):1293. doi: 10.3390/medicina57121293

Table 3.

Characteristics of study groups in terms of baseline visual acuity (BCVA).

Descriptive Statistics
n Minimum Maximum Average Standard Deviation
Aflibercept ETDRS_0—before therapy 90 35.0 80.0 59.9 14.08
Ranibizumab ETDRS_0—before therapy 54 35.0 80.0 60.7 12.18